SequelSEC

NeuroPace Inc NPCE

Surgical & Medical Instruments & Apparatus · CIK 0001528287 · Fiscal year ends 1231

Revenue
$99.99M
Fiscal year ended 2025-12-31
Operating income
-$16.34M
Fiscal year ended 2025-12-31
Free cash flow
-$11.34M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$306.20MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$9.09Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue3.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity16.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.3%5th
Long-term debt / equity3.09x94th
Gross margin77.2%85th
Current ratio5.28x77th
Revenue YoY growth25.1%71th
R&D / revenue27.9%63th
SBC / revenue11.1%61th
Operating margin-16.3%53th
FCF margin-11.3%51th
Net margin-21.5%51th

NeuroPace Inc (NPCE) reported revenue of $99.99M and net income of -$21.46M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from NeuroPace Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

NeuroPace Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Revenue$99.99M$79.91M$65.42M$45.52M$45.18M$41.14M
Cost of revenue$22.77M$20.82M$17.30M$13.03M$11.75M$10.87M
Gross profit$77.22M$59.08M$48.12M$32.49M$33.44M$30.27M
Operating income-$16.34M-$21.67M-$27.17M-$40.79M-$23.74M-$13.05M
Net income-$21.46M-$27.14M-$32.96M-$47.08M-$36.08M-$24.28M
Research & development$27.89M$23.65M$20.78M$21.95M$18.21M$15.70M
Weighted-average diluted sharesshares 32.72Mshares 29.13Mshares 25.85Mshares 24.59Mshares 16.61MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0UnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.66$-0.93$-1.27$-1.91$-2.17$-117.85
Selling, general & administrative$65.67M$57.10M$54.52M$51.34M$38.96M$27.63M
General & administrative$19.09M$17.43MUnavailableUnavailableUnavailableUnavailable
Selling & marketing$46.58M$39.67MUnavailableUnavailableUnavailableUnavailable

Balance

NeuroPace Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$21.69M$13.43M$18.06M$6.60M$19.19M$26.39M
Total assets$105.56M$94.65M$107.65M$114.11M$133.56M$55.95M
Current assets$94.07M$81.34M$92.72M$97.71M$132.82M$54.56M
Total liabilities$86.53M$86.63M$87.00M$79.33M$60.06M$62.36M
Current liabilities$17.81M$15.16M$16.23M$10.98M$9.30M$9.60M
Total equity incl. NCI$19.03M$8.01M$20.65M$34.78M$73.50M-$147.83M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$0$141.42M
Inventory$14.86M$13.38M$11.21M$9.71M$7.82M$6.91M
Accounts receivable$12.94M$12.85M$12.31M$7.48M$7.09M$8.40M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$58.88M$59.52M$56.95M$52.91M$49.85M$50.82M
Accounts payable$1.78M$2.95M$2.33M$2.15M$1.38M$949.00K

Cash flow

NeuroPace Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$11.01M-$17.95M-$19.70M-$36.87M-$24.58M-$21.61M
Capital expenditures$332.00K$306.00K$173.00K$603.00K$384.00K$62.00K
Investing cash flow-$332.00K$8.99M$23.03M$23.80M-$85.40M-$10.77M
Financing cash flow$19.60M$4.33M$8.13M$490.00K$102.53M$55.01M
Net change in cash$8.26M-$4.63M$11.45M-$12.58M-$7.45M$22.63M
Stock-based compensation$11.09M$10.28M$9.56M$8.35M$4.29M$1.38M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$49.55M$0UnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

NeuroPace Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$11.34M-$18.26M-$19.87M-$37.47M-$24.96M-$21.67M
Gross margin77.2%73.9%73.6%71.4%74.0%73.6%
Operating margin-16.3%-27.1%-41.5%-89.6%-52.5%-31.7%
FCF margin-11.3%-22.8%-30.4%-82.3%-55.2%-52.7%
SBC / revenue11.1%12.9%14.6%18.3%9.5%3.4%
Current ratio5.28x5.37x5.71x8.90x14.28x5.69x
Revenue YoY growth25.1%22.1%43.7%0.7%9.8%Unavailable
Net margin-21.5%-34.0%-50.4%-103.4%-79.9%-59.0%
R&D / revenue27.9%29.6%31.8%48.2%40.3%38.2%
CapEx / revenue0.3%0.4%0.3%1.3%0.8%0.2%
Long-term debt / equity3.09xUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open NPCE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-03View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.